Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NRX Pharmaceuticals (NRXP) just unveiled an update.
A company has announced through a press release that it has agreed on a non-binding term sheet, which could provide up to $7.5 million to refinance existing toxic debt, with a potential for an extra $22.5 million in additional funding. The total accessible capital could reach $30 million, but this is contingent upon successful due diligence and the finalization of binding agreements.
For a thorough assessment of NRXP stock, go to TipRanks’ Stock Analysis page.